# Wall Street's Wildest Stock Showdowns: Bulls vs. Bears!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-10-01T01:34:05.535Z
Source: https://newsyai.com/edition/91bc9e52-5947-446a-96d1-b72d80655a44
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Throwing Hands (and Maybe Some Feces) — Fresh Edition, October 1, 2026**[[1]](https://www.findmymoat.com/short-interest)[[2]](https://www.thetrading.tools/short-interest)

Futures mixed—Dow flat, Nasdaq mainlining the AI hype like it's the fountain of youth, crude oil bouncing like a caffeinated squirrel on a trampoline. Last round's deals-platform drama, AI-drug-discovery dice rolls, and Groupon ghost-town vibes? Yesterday's news. These three tickers have the Street more divided than a crypto bro at a family reunion. Elevated short interest across the board (flirting with 30-40%+ of float and days-to-cover that screams volatility potential), fresh short data, filings, and chatter only—no reruns. Bulls see structural tailwinds and squeeze fuel; bears see valuation traps, execution flops, dilution landmines, competition overhangs, and fading relevance. Then the first-principles hammer drops.[[3]](https://www.benzinga.com/trading-ideas/movers/26/09/62004722/squeeze-watch-10-stocks-with-over-33-short-interest)

### 1. Beam Therapeutics (BEAM) – Gene-Editing Wunderkind or Cash-Burning CRISPR Casino in a Regulatory Minefield?
BEAM sports elevated short interest (~39% of float in recent trackers, with days-to-cover around 12-13), with the market split on a base-editing platform for genetic diseases.[[4]](https://jp.benzinga.com/quote/BEAM/short-interest)

**Bull Case (The "Pipeline Momentum, First-Mover AATD Advantage, and Partnership Payday Crew")**  
Bulls highlight progress in BEAM-302 for alpha-1 antitrypsin deficiency (AATD) with potential first-mover edge, risto-cel and other candidates in the mix, analyst price targets implying massive upside (some north of $50-80), and partnerships that could de-risk development. Short interest hints at squeeze upside on positive clinical data or sector rallies. Some see it as a high-conviction play on precision gene editing delivering approved therapies.

**Bear Case (The "Clinical/Regulatory Risks, Serial Dilution/Dilution Risks, Competition from Bigger CRISPR Players, and 'Will It Ever Deliver Approved Drugs Without Burning Through Billions?' Crew")**  
Bears hammer on questions around converting early data to approved therapies, persistent negative cash flows requiring potential dilutive raises, entrenched competitors, and historical precedent of gene-editing plays struggling with timelines, safety signals, and profitability. Short buildup reflects skepticism that the vision justifies the price amid macro and execution hurdles.[[5]](https://seekingalpha.com/article/4950557-beam-therapeutics-ignore-the-anthropic-noise-and-focus-on-clinical-progress-upgrade)

**My First-Principles Take**: Biotech/gene-editing value accrues to platforms with proven scalability, defensible IP, sticky partnerships, and clear routes to positive margins—economics reward operational discipline and capital efficiency over pure tech bets in a regulation-, competition-, clinical validation-, and adoption-sensitive field. BEAM has genuine tailwinds from platform differentiation and momentum, but durable profits only come if cash burn moderates without endless dilution, differentiation sticks vs. bigger players, and pipeline converts to real value. The base-editing bet is directionally exposed to healthcare innovation trends, yet it's an execution-, capital-, and cycle-sensitive play prone to volatility and multiple compression. At these short levels, volatility grenade—positive catalysts roast shorts; weakness feeds the fire. High-risk, high-reward for the bold.

### 2. Intellia Therapeutics (NTLA) – CRISPR In Vivo Pioneer or Serial Diluter in a Biotech Graveyard?
NTLA carries notable short interest (~33-42% of float in recent trackers, with days-to-cover around 13-14), reflecting skepticism on a CRISPR gene-editing play.[[6]](https://chartexchange.com/symbol/nasdaq-ntla/short-interest/)

**Bull Case (The "HAE Priority Review Catalyst, ATTR Pipeline Depth, and One-Time Treatment Tailwinds Crew")**  
Bulls point to FDA priority review for lonvo-z in hereditary angioedema (HAE) with a March 2027 decision date, nex-z for ATTR amyloidosis advancing, new debt facility providing runway, analyst optimism, and potential for clinical validation to unlock re-rating. Short interest hints at squeeze upside on execution wins or sector rallies. Some see it as a high-conviction play on in vivo CRISPR delivering curative potential.

**Bear Case (The "Clinical Hold/Regulatory Risks, Cash Burn/Dilution Risks, Competition Overhang, and 'Will It Ever Deliver Without Endless Raises?' Crew")**  
Bears hammer on questions around clinical holds or delays, persistent negative cash flows requiring potential dilutive raises, entrenched competitors, and historical precedent of CRISPR/biotech plays struggling with timelines and profitability. Short buildup reflects skepticism that the vision justifies the price amid macro and execution hurdles.[[7]](https://kalkine.com/news/healthcare/why-an-fda-decision-could-trigger-a-short-squeeze-in-intellia-therapeutics-nasdaqntla-stock)

**My First-Principles Take**: Biotech/CRISPR value accrues to concepts with proven scalability, cost-competitive development economics, sticky partnerships, and clear routes to positive margins—economics reward operational discipline and capital efficiency over pure tech bets in a regulation-, competition-, clinical validation-, and adoption-sensitive field. NTLA has genuine tailwinds from pipeline differentiation and catalysts, but durable profits only come if cash burn moderates without endless dilution, differentiation sticks vs. bigger players, and pipeline converts to real value. The in vivo CRISPR bet is directionally exposed to healthcare innovation trends, yet it's an execution-, capital-, and cycle-sensitive play prone to volatility and multiple compression. At these short levels, volatility grenade—positive catalysts roast shorts; weakness feeds the fire. High-risk, high-reward for the bold.

### 3. Eos Energy Enterprises (EOSE) – Zinc Battery Storage Disruptor or Serial Cash Incinerator in a Commoditized Energy Graveyard?
EOSE features elevated short interest (~33% of float in recent trackers, with days-to-cover around 4), with the market split on a zinc-based battery play for grid-scale storage.[[8]](https://curvedtrading.com/stocks/eose/)

**Bull Case (The "Revenue Surge, Massive Backlog, DOE Funding, and Non-Lithium Safety Edge Crew")**  
Bulls highlight surging revenue (hundreds of percent YoY growth), record backlog and commercial wins, DOE loan advances for manufacturing scale-up, Frontier JV partnerships, and differentiation in safety/long-duration vs. lithium. Short interest hints at squeeze upside on order conversions or sector rallies. Some see it as a high-conviction play on energy storage demand from renewables, AI data centers, and utilities.

**Bear Case (The "Cash Burn/Dilution Risks, Debt Load, Manufacturing Scale Challenges, and 'Will It Ever Turn Profitable?' Crew")**  
Bears cite ongoing questions around converting backlog to cash flow, persistent negative cash flows and dilution, high debt, production ramp hurdles, and historical precedent of battery/tech plays struggling with profitability. Short buildup reflects skepticism that the vision justifies the price amid macro and execution hurdles.[[9]](https://kalkine.com/news/industrials/why-eos-energy-nasdaqeose-stock-looks-too-cheap-to-short-despite-a-75-drop-this-year)

**My First-Principles Take**: Energy storage value accrues to players with defensible tech/IP, scalable manufacturing, diversified end-markets, and paths to positive unit economics/margins—economics reward capital discipline and market adaptation over pure R&D bets in a competition-, technology adoption-, capex-, and cycle-sensitive field. EOSE has genuine tailwinds from targeted growth areas and product momentum, but durable profits only come if cash burn moderates without endless dilution, differentiation holds vs. rivals, and revenue scales meaningfully. The zinc-battery bet is directionally exposed to grid modernization trends, yet it's an execution-, capital-, and macro-sensitive play prone to volatility and multiple compression. At these short levels, volatility rocket fuel—catalysts roast bears; stumbles feed the fire.

There you have it—three fresh brawls proving disagreement is the market's favorite drug. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short interest data (e.g., FINRA via trackers like FindMyMoat, MarketBeat, Benzinga, ShortInterestTracker, AltIndex, and related screens), company filings/press releases, analyst notes, and options flow as of late September/early October 2026. Trade responsibly, you magnificent animals.
